Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02295475 · ClinicalTrials.gov registry record · Phase 4

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

A Phase 4 study of Thrombosis and Antiphospholipid Syndrome, sponsored by Scott C. Woller, MD.

Completed
Registry status
Phase 4
Development phase
48
Enrollment target
2
Study locations

NCT02295475: Completed Phase 4 study of Thrombosis and Antiphospholipid Syndrome, sponsored by Scott C. Woller, MD.

NCT02295475 is a Phase 4 study of Thrombosis and Antiphospholipid Syndrome that has completed, run by Scott C. Woller, MD. The registered enrollment target is 48 participants, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02295475, a Phase 4 study of Thrombosis and Antiphospholipid Syndrome, has completed, sponsored by Scott C. Woller, MD.

COMPLETED
Registry status
Phase 4
Development phase
48 participants
Enrollment target
2
Study locations

Study Summary

This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a condition called "antiphospholipid syndrome".

Conditions Studied

Thrombosis Antiphospholipid Syndrome

Interventions

  • DRUG Apixaban
  • DRUG Warfarin

Study Locations (2)

Ohio

  • The James Comprehensive Cancer Center - Columbus

Utah

  • Intermountain Medical Center - Murray

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2014-12-10
Est. Completion 2022-03
Phase Phase 4
Scott C. Woller, MD

2 total trials

What the finished NCT02295475 record still lists

NCT02295475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.

NCT02295475 reports a single indexed study location in Ohio, Utah.

Frequently Asked Questions

What is clinical trial NCT02295475 about?

NCT02295475 is a clinical study titled "Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome". This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a condition called "antiphospholipid syndrome".

What is the current status of trial NCT02295475?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2014-12-10. Estimated completion is 2022-03.

What conditions does trial NCT02295475 study?

This clinical trial studies the following conditions: Thrombosis, Antiphospholipid Syndrome.

What interventions are being tested in trial NCT02295475?

The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG).

Who is sponsoring clinical trial NCT02295475?

This trial is sponsored by Scott C. Woller, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02295475 being conducted?

This trial has 2 study locations across Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thrombosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02295475's enrollment target sits among peer trials

48 16th of 28 higher than 13 of 28 other Thrombosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02295475, the US trial registry maintained by the National Library of Medicine. NCT02295475 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.